2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Diseases, Hemoglobinopathies, Thalassemia, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Young Adult, Animal Model
PAPER

4254 Microbiota-derived 12-ketolithocholic acid attenuates acute graft-versus-host disease by reprogramming donor T-cell fate and restoring enterohepatic bile acid homeostasis

Pengfei Li, PhD, Zhihua Liu2, Xinghao Yu3, Yang Xu, MD4, Depei Wu Sr, MD5
1 The First Affiliated Hospital of Soochow University, Soochow, Jiangsu Province, China
2 The First Affiliated Hospital of Soochow University, Soochow, Jiangsu Province, China
3 The First Affiliated Hospital of Soochow University, Soochow, Jiangsu Province, China
4 The First Affiliated Hospital of Soochow University, Soochow, Jiangsu Province, China
5 The First Affiliated Hospital of Soochow University, Soochow, Jiangsu Province, China

Background: Gastrointestinal acute graft-versus-host disease (GI-aGVHD) remains a major cause of morbidity and mortality post allogeneic hematopoietic stem cell transplantation (allo-HSCT). Emerging evidence highlights the critical role of the gut microbiota in the development and progression of GI-aGVHD. We previously showed that the Bacteroidetes type VI secretion system remodels the gut microbiota and bile acid pool, preserves intestinal barrier integrity, and reduces GI-aGVHD. However, the specific microbiota-derived bile acid metabolites that mediate this protective effect, and their underlying immunoregulatory mechanisms remain largely undefined. This study aims to identify functional bile acids that protects against aGVHD and to define its immunologic and metabolic mechanisms.

Methods: Targeted fecal bile acid metabolomics was performed in syngeneic and allogeneic transplant mice to identify metabolites associated with aGVHD severity. The leading candidate, 12-ketolithocholic acid (12-ketoLCA), was evaluated in a murine aGVHD model. Donor CD4+ T-cell differentiation was assessed by flow cytometry in aGVHD targeted organs, together with naïve CD4+ T cell differentiation assays in vitro. Single-cell RNA sequencing, paired T-cell receptor sequencing, differentiation trajectory analysis, and cell communication inference were integrated to characterize intestinal T cell states, clonal architecture, and immune stromal interactions. Gut microbial composition and hepatic bile acid synthesis were analyzed to assess enterohepatic homeostasis. Molecular docking and affinity-based mass spectrometry were used to prioritize candidate bile acid-sensing receptors linked to T-bet/GATA3 regulation.

Results: 12-ketoLCA was identified as a microbiota-derived bile acid inversely associated with aGVHD severity. In allogeneic transplant mice, 12-ketoLCA attenuated disease severity and consistently reduced pathogenic Th1 responses in the intestine, spleen, and liver, while directly inhibiting Th1 differentiation in vitro. Integrated single-cell RNA and TCR sequencing showed that 12-ketoLCA shifted donor T cells from a Th1-dominant state toward Th2 and Treg associated programs, increased clonal diversity, and dispersed Th1-associated clonotypes. Cell communication analysis revealed reduced antigen-presentation and adhesion signaling, including MHC-I/MHC-II, and ITGAL-ITGB2 pathways, supporting a model in which 12-ketoLCA reprograms donor T cell fate, and restores the intestinal immune-stromal niche. In parallel, 12-ketoLCA reshaped the gut microbiota and restored hepatic de novo bile acid synthesis, establishing a self-reinforcing microbiota-bile acid-immune circuit. Molecular docking and affinity-based mass spectrometry further identified a candidate receptor network, including AHR, that may coordinate T-bet/GATA3-dependent differentiation.

Conclusions: This study identifies 12-ketoLCA as a microbial metabolite that reprograms donor T cell differentiation fate and restores enterohepatic bile acid homeostasis. These findings establish a mechanistic link between microbial bile acid metabolism and donor T cell fate, and nominate 12-ketoLCA and its receptor pathway as tractable targets for microbiome-based prevention and treatment of aGVHD.

Pengfei Li, PhD: No relevant conflicts of interest to declare.